» Articles » PMID: 38973612

IL-10 Inhibition During Immunization Improves Vaccine-induced Protection Against Staphylococcus Aureus Infection

Overview
Journal JCI Insight
Date 2024 Jul 8
PMID 38973612
Authors
Affiliations
Soon will be listed here.
Abstract

Staphylococcus aureus is a major human pathogen. An effective anti-S. aureus vaccine remains elusive as the correlates of protection are ill-defined. Targeting specific T cell populations is an important strategy for improving anti-S. aureus vaccine efficacy. Potential bottlenecks that remain are S. aureus-induced immunosuppression and the impact this might have on vaccine-induced immunity. S. aureus induces IL-10, which impedes effector T cell responses, facilitating persistence during both colonization and infection. Thus, it was hypothesized that transient targeting of IL-10 might represent an innovative way to improve vaccine efficacy. In this study, IL-10 expression was elevated in the nares of persistent carriers of S. aureus, and this was associated with reduced systemic S. aureus-specific Th1 responses. This suggests that systemic responses are remodeled because of commensal exposure to S. aureus, which negatively implicates vaccine function. To provide proof of concept that targeting immunosuppressive responses during immunization may be a useful approach to improve vaccine efficacy, we immunized mice with T cell-activating vaccines in combination with IL-10-neutralizing antibodies. Blocking IL-10 during vaccination enhanced effector T cell responses and improved bacterial clearance during subsequent systemic and subcutaneous infection. Taken together, these results reveal a potentially novel strategy for improving anti-S. aureus vaccine efficacy.

Citing Articles

in Inflammation and Pain: Update on Pathologic Mechanisms.

Rasquel-Oliveira F, Ribeiro J, Martelossi-Cebinelli G, Costa F, Nakazato G, Casagrande R Pathogens. 2025; 14(2).

PMID: 40005560 PMC: 11858194. DOI: 10.3390/pathogens14020185.


Pathobiont-induced suppressive immune imprints thwart T cell vaccine responses.

Hajam I, Tsai C, Gonzalez C, Caldera J, Lazaro Diez M, Du X Nat Commun. 2024; 15(1):10335.

PMID: 39681568 PMC: 11649901. DOI: 10.1038/s41467-024-54644-w.

References
1.
Ndure J, Flanagan K . Targeting regulatory T cells to improve vaccine immunogenicity in early life. Front Microbiol. 2014; 5:477. PMC: 4161046. DOI: 10.3389/fmicb.2014.00477. View

2.
Peacock S, Justice A, Griffiths D, de Silva G, Kantzanou M, Crook D . Determinants of acquisition and carriage of Staphylococcus aureus in infancy. J Clin Microbiol. 2003; 41(12):5718-25. PMC: 308978. DOI: 10.1128/JCM.41.12.5718-5725.2003. View

3.
Greenhill C, Jones G, Nowell M, Newton Z, Harvey A, Moideen A . Interleukin-10 regulates the inflammasome-driven augmentation of inflammatory arthritis and joint destruction. Arthritis Res Ther. 2014; 16(4):419. PMC: 4292830. DOI: 10.1186/s13075-014-0419-y. View

4.
Mousavi-Niri N, Naseroleslami M, Hadjati J . Anti-regulatory T cell vaccines in immunotherapy: focusing on FoxP3 as target. Hum Vaccin Immunother. 2019; 15(3):620-624. PMC: 6605713. DOI: 10.1080/21645515.2018.1545625. View

5.
Chan L, Chaili S, Filler S, Barr K, Wang H, Kupferwasser D . Nonredundant Roles of Interleukin-17A (IL-17A) and IL-22 in Murine Host Defense against Cutaneous and Hematogenous Infection Due to Methicillin-Resistant Staphylococcus aureus. Infect Immun. 2015; 83(11):4427-37. PMC: 4598415. DOI: 10.1128/IAI.01061-15. View